Your browser is no longer supported. Please, upgrade your browser.
VIE Viela Bio, Inc. daily Stock Chart
Viela Bio, Inc.
Index- P/E- EPS (ttm)-2.36 Insider Own1.30% Shs Outstand55.57M Perf Week0.13%
Market Cap2.11B Forward P/E- EPS next Y-2.34 Insider Trans0.00% Shs Float22.18M Perf Month-7.54%
Income-86.40M PEG- EPS next Q-0.73 Inst Own37.30% Short Float4.19% Perf Quarter46.44%
Sales50.00M P/S42.23 EPS this Y54.60% Inst Trans- Short Ratio9.89 Perf Half Y-
Book/sh9.68 P/B3.93 EPS next Y21.70% ROA- Target Price50.25 Perf Year-
Cash/sh5.66 P/C6.71 EPS next 5Y- ROE- 52W Range18.20 - 70.66 Perf YTD39.96%
Dividend- P/FCF- EPS past 5Y- ROI-25.30% 52W High-50.47% Beta-
Dividend %- Quick Ratio11.90 Sales past 5Y- Gross Margin- 52W Low92.31% ATR7.53
Employees139 Current Ratio11.90 Sales Q/Q- Oper. Margin- RSI (14)46.39 Volatility14.44% 24.19%
OptionableNo Debt/Eq0.00 EPS Q/Q26.20% Profit Margin- Rel Volume0.64 Prev Close38.00
ShortableYes LT Debt/Eq0.00 EarningsMar 25 AMC Payout- Avg Volume94.03K Price35.00
Recom2.00 SMA20-12.80% SMA50-13.36% SMA2009.07% Volume45,574 Change-7.89%
Feb-18-20Initiated H.C. Wainwright Buy $60
Feb-04-20Downgrade Goldman Buy → Neutral $36
Oct-28-19Initiated Morgan Stanley Overweight $25
Oct-28-19Initiated Guggenheim Buy $44
Oct-28-19Initiated Goldman Buy $32
Oct-28-19Initiated Cowen Outperform
Mar-25-20 04:15PM  Viela Bio Reports Fourth Quarter and Full Year 2019 Financial Results and Business Highlights GlobeNewswire -13.47%
03:00PM  Viela Bio Inc to Host Earnings Call ACCESSWIRE
Mar-18-20 09:38AM  Why Viela Bio (VIE) Might Surprise This Earnings Season Zacks -5.52%
07:00AM  Viela Bio to Webcast Fourth Quarter and Full Year 2019 Operating and Financial Results on March 25, 2020 GlobeNewswire
Mar-11-20 09:32AM  Why Earnings Season Could Be Great for Viela Bio (VIE) Zacks +6.23%
Feb-26-20 08:42AM  Is a Surprise Coming for Viela Bio (VIE) This Earnings Season? Zacks +9.10%
Dec-11-19 07:00AM  Viela Bio Announces Initiation of Phase 2b Trial of VIB4920 in Sjögrens Syndrome GlobeNewswire
Nov-14-19 04:00PM  Viela Bio Reports Third Quarter 2019 Financial Results and Business Highlights GlobeNewswire -5.13%
Nov-12-19 11:40AM  3 Strong Buy Biotech Stocks That Recently Went Public TipRanks
Oct-11-19 05:01PM  Gates-Backed Vir Biotechnology Flops in Trading Debut Bloomberg
Oct-09-19 06:00AM  Viela Bio Enters Strategic Collaboration with Mitsubishi Tanabe Pharma to Develop and Commercialize Inebilizumab for Autoimmune Diseases in Japan and Other Asia Regions GlobeNewswire -9.22%
Oct-07-19 04:05PM  Viela Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire -5.97%
Oct-03-19 02:49PM  UPDATE: Viela Bio jumps 27% in trading debut MarketWatch
Oct-02-19 09:54PM  Viela Bio Announces Pricing of Initial Public Offering GlobeNewswire
Viela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjogren's syndrome; and VIB7734 for cutaneous lupus erythematosus. Viela Bio, Inc. has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ragatz WilliamVP, Head of CommercialJan 27Option Exercise5.2216,25084,82516,250Jan 29 06:33 PM